These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risk of Nondherence to Diabetes Medications Among Medicare Advantage Enrollees: Development of a Validated Risk Prediction Tool. Mhatre SK, Serna O, Sansgiry S, Fleming ML, Essien EJ, Sansgiry SS. J Manag Care Spec Pharm; 2016 Nov; 22(11):1293-1301. PubMed ID: 27783546 [Abstract] [Full Text] [Related]
3. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes. Bibeau WS, Fu H, Taylor AD, Kwan AY. J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549 [Abstract] [Full Text] [Related]
4. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study. Chinthammit C, Axon DR, Mollon L, Taylor AM, Pickering M, Black H, Warholak T, Campbell PJ. J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445 [Abstract] [Full Text] [Related]
5. Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study. Sheer R, Bunniran S, Uribe C, Fiscella RG, Patel VD, Chandwani HS. J Manag Care Spec Pharm; 2016 Jul; 22(7):808-817a. PubMed ID: 27348282 [Abstract] [Full Text] [Related]
6. Disparities in Initial Oral Antidiabetic Medication Adherence Among Veterans with Incident Diabetes. Gatwood JD, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, Kovesdy CP. J Manag Care Spec Pharm; 2018 Apr; 24(4):379-389. PubMed ID: 29578849 [Abstract] [Full Text] [Related]
7. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy. Schwab P, Racsa P, Rascati K, Mourer M, Meah Y, Worley K. J Manag Care Spec Pharm; 2019 Mar; 25(3):332-340. PubMed ID: 30816817 [Abstract] [Full Text] [Related]
8. Development and validation of a drug adherence index for COPD. Bengtson LGS, Bancroft T, Schilling C, Buikema AR, Stanford RH. J Manag Care Spec Pharm; 2021 Feb; 27(2):198-209. PubMed ID: 33506734 [Abstract] [Full Text] [Related]
9. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes. Levin PA, Zhou S, Gill J, Wei W. J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966 [Abstract] [Full Text] [Related]
10. Medication Nonadherence Among Medicare Beneficiaries with Comorbid Chronic Conditions: Influence of Pharmacy Dispensing Channel. Iyengar RN, LeFrancois AL, Henderson RR, Rabbitt RM. J Manag Care Spec Pharm; 2016 May; 22(5):550-60. PubMed ID: 27123916 [Abstract] [Full Text] [Related]
11. The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database. Eby EL, Bajpai S, Faries DE, Haynes VS, Lage MJ. J Manag Care Spec Pharm; 2020 Sep; 26(9):1081-1089. PubMed ID: 32857656 [Abstract] [Full Text] [Related]
12. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents. Kim K, Unni S, McAdam-Marx C, Thomas SM, Sterling KL, Olsen CJ, Johnstone B, Mitchell M, Brixner D. J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811 [Abstract] [Full Text] [Related]
13. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Buysman EK, Liu F, Hammer M, Langer J. Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470 [Abstract] [Full Text] [Related]
14. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors. Rascati KL, Worley K, Meah Y, Everhart D. J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454 [Abstract] [Full Text] [Related]
15. Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer. Hess LM, Louder A, Winfree K, Zhu YE, Oton AB, Nair R. J Manag Care Spec Pharm; 2017 Jun; 23(6):643-652. PubMed ID: 28530522 [Abstract] [Full Text] [Related]
16. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence. Amin K, Farley JF, Maciejewski ML, Domino ME. J Manag Care Spec Pharm; 2017 Mar; 23(3):337-345. PubMed ID: 28230447 [Abstract] [Full Text] [Related]
17. Impact of a Combined Value-Based Insurance Design and Medication Therapy Management Program on Diabetes Medication Adherence. Peaslee A, Wickizer M, Olson J, Topp R. J Manag Care Spec Pharm; 2016 Nov; 22(11):1303-1309. PubMed ID: 27783550 [Abstract] [Full Text] [Related]
18. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States. Durden E, Liang M, Fowler R, Panton UH, Mocevic E. J Manag Care Spec Pharm; 2019 Jun; 25(6):669-680. PubMed ID: 30896359 [Abstract] [Full Text] [Related]
19. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications. Majd Z, Mohan A, Paranjpe R, Abughosh SM. J Manag Care Spec Pharm; 2021 Feb; 27(2):186-197. PubMed ID: 33506725 [Abstract] [Full Text] [Related]
20. Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes. Tan E, Yang W, Pang B, Dai M, Loh FE, Hogan P. J Manag Care Spec Pharm; 2015 Dec; 21(12):1195-202. PubMed ID: 26679968 [Abstract] [Full Text] [Related] Page: [Next] [New Search]